Abstract
COVID-19 is reported to have been effectively brought under control in China at its initial start place. To understand the COVID-19 outbreak in China and provide potential lessons for other parts of the world, in this study we combine a mathematical modelling with multiple datasets to estimate its transmissibility and severity and how it was affected by the unprecedented control measures. Our analyses show that before 29th January 2020, the ascertainment rate is 6.9%(95%CI: 3.5 – 14.6%); then it increased to 41.5%(95%CI: 30.6 – 65.1%). The basic reproduction number (R0) was 2.23(95%CI: 1.86 – 3.22) before 8th February 2020; then it dropped to 0.04(95%CI: 0.01 – 0.10). This estimation also indicates that the effect on transmissibility of control measures taken since 23rd January 2020 emerged about two weeks late. The confirmed case fatality rate is estimated at 4.41%(95%CI: 3.65 – 5.30%). This shows that SARS-CoV-2 virus is highly transmissible but less severe than SARS-CoV-1 and MERS-CoV. We found that at the early stage, the majority of R0 comes from the undetected infected people. This implies that the successful control in China was achieved through decreasing the contact rates among people in general populations and increasing the rate of detection and quarantine of the infected cases.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
None because this is a theoretical study
Funding Statement
This work is jointly supported by Public Health England, UK and Innovative Research Team of Yunnan Province (2019(6)), China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are given in the paper
